Honjo 1995.

Methods	Design: placebo‐ controll ed, double‐blind parallel groups, 7 weeks
Participants	Country: Japan n=14 AD (criteria?) (13 completers), mild dementia (MMSE: 18 SD 6). Aged 84 (SD 5). Natural menopause (bleeding). No exclusion criteria ?
Interventions	1. CEE oral 1.25 mg /day for 3 wks + MPA 2.5 mg/day for last 3 weeks 2. Placebo
Outcomes	General (MMSE and Japanese dementia scales: NSD HDS)
Notes	HRT: all improved > baseline, 3/3 test. No between groups effect. Adverse events: 11 vaginal bleeding